{
    "medicine_id": "50b8a6cf38575b7b581cdcd163b52aa9d61f0afd",
    "platform_id": "DB15940",
    "metadata": {
        "name": "Imdevimab 300 mg 2 5mL Injection solution concentrate",
        "composition": "300 mg 2 5mL Imdevimab",
        "clinical_particulars": {
            "therapeutic_indications": "According to the Emergency Use Authorization EUA by the FDA indevimab is used only with casirivimab to treat mild to moderate COVID 19 from laboratory confirmed SARS CoV 2 infection in adults and children aged 12 years of age and older weighing at least 40 kg Treatment is reserved for patients who are at high risk for progressing to require hospitalization or severe COVID 19 L23524 L23534 This combination may only be administered by intravenous infusion in healthcare settings with immediate access to treatment for infusion reactions and anaphylaxis and the ability to activate the emergency medical system EMS as required L23534 L23539 Limitations of use Imdevimab and casirivimab is not for use in patients currently hospitalized due to COVID 19 patients requiring oxygen therapy due to COVID 19 patients requiring increases in baseline oxygen flow rate from COVID 19 or patients on oxygen therapy for non COVID 19 related morbidity L23524 L23534",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Casirivimab and imdevimab work to neutralize the spike protein of SARS CoV 2 L23524 In a clinical trial casirivimab and imdevimab when given together reduced COVID 19 related hospitalization or emergency room visits in patients diagnosed with COVID 19 who were at high risk for disease progression within 28 days after treatment No benefit has been shown in patients already hospitalized due to COVID 19 receiving this combination L23539",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}